Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/12673
Título : Evaluating the potential of Ursolic Acid as bioproduct for cutaneous and visceral leishmaniasis
Autor : Bilbao Ramos, Pablo.
Serrano López, Dolores Remedios.
Ruiz Saldaña, Helga Karina.
Torrado Durán, Juan José.
Bolás Fernández, Francisco.
Dea Ayuela, María Auxiliadora.
Materias: Leishmaniasis - Tratamiento.Leishmaniasis - Treatment.Enfermedades infecciosas - Tratamiento.Ursolic acid - Therapeutic use.Ácido ursólico - Uso terapéutico.Citoquina.Cytokines.Communicable diseases - Treatment.
Fecha de publicación : 19-mar-2020
Editorial : MDPI.
Citación : Bilbao-Ramos, P., Serrano, D.R., Ruiz Saldaña, H.K., Torrado, J.J., Bolás-Fernández, F. & Dea-Ayuela, M.A. (2020). Evaluating the potential of Ursolic Acid as bioproduct for cutaneous and visceral leishmaniasis. Molecules, vol. 25, i. 6 (19 mar.), art. 1394. DOI: https://doi.org/10.3390/molecules25061394
Resumen : Leishmaniasis a ects around 12 million people worldwide and is estimated to cause the ninth-largest disease burden. There are three main forms of the disease, visceral (VL), cutaneous (CL), and mucocutaneous (MCL), leading to more than one million new cases every year and several thousand deaths. Current treatments based on chemically synthesized molecules are far from ideal. In this study, we have tested the in vitro and in vivo e cacy of ursolic acid (UA), a multifunctional triterpenoid with well-known antitumoral, antioxidant, and antimicrobial e ects on di erent Leishmania strains. The in vitro antileishmanial activity against the intracellular forms was six and three-fold higher compared to extracellular forms of L. amazonensis and L. infantum, respectively. UA also showed to be a potent antileishmanial drug against both VL and CL manifestations of the disease in experimental models. UA parenterally administered at 5 mg/kg for seven days significantly reduced the parasite burden in liver and spleen not only in murine acute infection but also in a chronic-infection model against L. infantum. In addition, UA ointment (0.2%) topically administered for four weeks diminished (50%) lesion size progression in a chronic infection model of CL caused by L. amazonensis, which was much greater than the e ect of UA formulated as an O/W emulsion. UA played a key role in the immunological response modulating the Th1 response. The exposure of Leishmania-infected macrophages to UA led to a significant di erent production in the cytokine levels depending on the Leishmania strain causing the infection. In conclusion, UA can be a promising therapy against both CL and VL.
Descripción : Este artículo se encuentra disponible en la siguiente URL: https://www.mdpi.com/1420-3049/25/6/1394
Este artículo pertenece al número especial "Bioproducts for health".
URI : http://hdl.handle.net/10637/12673
Derechos: http://creativecommons.org/licenses/by/4.0/deed.es
ISSN : 1420-3049 (Electrónico).
Aparece en las colecciones: Dpto. Farmacia

Ficheros en este ítem:
Fichero Tamaño Formato  
Evaluating_Bilbao_MOLECULES_2020.pdf695,38 kBAdobe PDFVisualizar/Abrir



Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.